HPLC method development and validation for simultaneous determination of lamivudine and tenofovir in tablet dosage


Volume :

4

Issue :

3

Abstract :

A simple, reverse-phase high performance liquid chromatographic method has been developed and validated for the simultaneous estimation of Lamivudine and Tenofovir disoproxil fumarate in pure and tablet dosage form. The chromatographic Separation was carried out using on Hypersil BDS C18 column (250 x4.6mm id, 5m particle size) in isocratic mode with flow rate of 1mLmin-1 and the detection was carried out by photo diode array detector at 260nm. The mobile phase consists of 0.01N Sodium Dihydrogen Ortho Phosphate Buffer (pH 4.5±0.5) and acetonitrile in the ratio of 50:50 (v/v). The retention time for Lamivudine and Tenofovir was found to be 2.18mins and 3.64mins respectively. The linearity was obtained in the concentration range of 75- 450µgmL-1 for both the Lamivudine and Tenofovir Disoproxil Fumarate. The LOD was found 0.92µgmL-1 and 2.37µgmL-1 for Lamivudine and Tenofovir respectively, whereas LOQ was found to be 2.79µgmL-1 for Lamivudine and 7.17µgmL-1 for Tenofovir. The percentage recovery was found to be 99.84 – 100.54 for Lamivudine and 99.72 – 100.82 for Tenofovir respectively. The method was statistically validated as per ICH guidelines and %RSD was found to be less than 2 indicating high degree of accuracy and precision of the proposed HPLC method.
Journals Insights Open Access Journal Filmy Knowledge Hanuman Devotee Avtarit Wiki In Hindi Multiple Choice GK